Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Abstract. Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, res...

Full description

Bibliographic Details
Main Authors: Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
Format: Article
Language:English
Published: Wolters Kluwer 2020-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000363

Internet

http://journals.lww.com/10.1097/HS9.0000000000000363

Similar Items